Stock Traders Purchase Large Volume of Call Options on Neuronetics (NASDAQ:STIM)

Neuronetics, Inc. (NASDAQ:STIM) saw unusually large options trading on Thursday. Stock traders acquired 5,519 call options on the company. This is an increase of 905% compared to the average daily volume of 549 call options.

Analyst Upgrades and Downgrades

STIM has been the subject of several analyst reports. Wall Street Zen raised shares of Neuronetics from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neuronetics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Institutional Trading of Neuronetics

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Neuronetics by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,832,118 shares of the company’s stock valued at $7,732,000 after purchasing an additional 89,504 shares during the period. UBS Group AG lifted its holdings in Neuronetics by 580.7% in the 3rd quarter. UBS Group AG now owns 2,164,831 shares of the company’s stock worth $5,910,000 after buying an additional 1,846,801 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in Neuronetics by 6.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,509,099 shares of the company’s stock valued at $5,267,000 after buying an additional 92,048 shares during the last quarter. Wexford Capital LP grew its stake in shares of Neuronetics by 83.1% during the third quarter. Wexford Capital LP now owns 1,177,225 shares of the company’s stock valued at $3,214,000 after acquiring an additional 534,155 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Neuronetics by 172.3% during the second quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock valued at $3,068,000 after acquiring an additional 556,268 shares in the last quarter. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Neuronetics Stock Performance

NASDAQ:STIM opened at $2.13 on Friday. The company has a market cap of $145.88 million, a P/E ratio of -2.60 and a beta of 0.66. The firm’s 50 day moving average is $1.56 and its two-hundred day moving average is $2.67. Neuronetics has a fifty-two week low of $1.25 and a fifty-two week high of $5.92. The company has a quick ratio of 2.09, a current ratio of 2.24 and a debt-to-equity ratio of 2.09.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $37.30 million for the quarter, compared to analysts’ expectations of $37.85 million. Neuronetics had a negative net margin of 33.88% and a negative return on equity of 131.15%. Analysts expect that Neuronetics will post -1.13 EPS for the current year.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.